Smart Hydrogel Targets Osteoarthritis by Restoring Mitochondrial Health in Joints

Osteoarthritis (OA) affects hundreds of millions globally and lacks disease-modifying therapies. Current treatments manage pain but do not halt joint degeneration. A key driver of OA is the destructive crosstalk among oxidative stress, chronic inflammation, and cellular aging — collectively termed the oxi-inflamm-aging network — which destabilizes chondrocytes, the cells responsible for maintaining cartilage integrity.

Researchers at Xijing Hospital and Xidian University developed a nanocomposite hydrogel system designed to simultaneously attack all three arms of this network. Central to the strategy is a chimeric peptide called MW, which fuses MOTS-s (a mitochondria-protective peptide) with WYRGRL (a cartilage-targeting sequence). This dual-function peptide was loaded onto two-dimensional GeSe nanosheets, which possess intrinsic enzyme-mimicking (nanozyme) activity capable of neutralizing reactive oxygen species.

The GeSe-peptide construct was embedded in a responsive hydrogel matrix (HMP) composed of hyaluronic acid-maleimide, an MMP13-sensitive peptide linker, and Pluronic F127. The MMP13-cleavable linker enables targeted payload release specifically within the arthritic joint microenvironment, where MMP13 is overexpressed.

In vitro and in vivo experiments demonstrated that MW@GeSe@HMP effectively suppressed oxidative damage, reduced inflammatory signaling, and attenuated cellular senescence in chondrocytes. Mechanistically, the treatment inhibited the cGAS/STING pathway, a key innate immune sensor that links mitochondrial dysfunction to chronic inflammation. In a rat OA model, the hydrogel significantly reduced cartilage degradation and matrix loss.

While results are promising, the study is limited to preclinical models. Translation to human OA requires safety profiling of GeSe nanosheets, assessment of long-term joint retention, and validation in larger animal models before clinical trials can be considered.